Stockreport

SAB Biotherapeutics Appoints Mark J. Ratain, MD, to The Company's Board Of Scientific Advisors [TheStreet.com]

SAB Biotherapeutics, Inc.  (SABS) 
PDF novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the [Read more]